Adult height in short normal adolescent girls treated with gonadotropin-releasing hormone analog and growth hormone.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Leuprolide in this clinical trial publication.

At the onset of treatment, chronological age was 11.6 +/- 1.4 yr, bone age was 10.6 +/- 0.9 yr, height was -2.7 +/- 0.7 SD, predicted height (PH; Bayley-Pinneau score) was 143.2 +/- 3 cm.

Target height was 147.6 +/- 5.6 cm.

Who Took Part

The study group was 10 girls.

The age groups tagged for this paper are teenagers, women only.

The combined therapies were started simultaneously, and the patients were treated for 28.1 +/- 5.4 (range, 24-36) months.

What Was Measured

At the onset of treatment, chronological age was 11.6 +/- 1.4 yr, bone age was 10.6 +/- 0.9 yr, height was -2.7 +/- 0.7 SD, predicted height (PH; Bayley-Pinneau score) was 143.2 +/- 3 cm.

Statistical analysis was performed using Student's t test for paired data.

Topics PubMed links to this paper include Body Height, Bone Development, Estradiol, Forecasting, Gonadotropin-Releasing Hormone, Gonadotropins and Growth Disorders.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Leuprolide in 10 girls.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1995 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Leuprolide compound page, all human trials.